An ultra-high throughput cell-based screen for wee1 degradation inhibitors.
The tyrosine kinase Wee1 is part of a key cellular sensing mechanism that signals completion of DNA replication, ensuring proper timing of entry into mitosis. Wee1 acts as an inhibitor of mitotic entry by phosphorylating cyclin-dependent kinase CDK1. Wee1 activity is mainly regulated at the protein level through its phosphorylation and subsequent degradation by the ubiquitin proteasome pathway. To facilitate identification of small molecules preventing Wee1 degradation, a homogeneous cell-based assay was developed using HeLa cells transiently transfected with a Wee1-luciferase fusion protein. To ensure ultra-high-throughput screening (uHTS) compatibility, the assay was scaled to a 1536-well plate format and cells were transfected in bulk and cryopreserved. This miniaturized homogeneous assay demonstrated robust performance, with a calculated Z' factor of 0.65 +/- 0.05. The assay was screened against a publicly available library of approximately 218,000 compounds to identify Wee1 stabilizers. Nonselective, cytotoxic, and promiscuous compounds were rapidly triaged through the use of a similarly formatted counterscreen that measured stabilization of an N-cyclin B-luciferase fusion protein, as well as execution of viability assessment in the parental HeLa cell line. This screening campaign led to the discovery of 4 unrelated cell-permeable small molecules that showed selective Wee1-luciferase stabilization with micromolar potency. One of these compounds, SID4243143 (ML 118), was shown to inhibit cell cycle progression, underscoring the importance of Wee1 degradation to the cell cycle. Results suggest that this uHTS approach is suitable for identifying selective chemical probes that prevent Wee1 degradation and generally applicable to discovering inhibitors of the ubiquitin proteasome pathway.
Madoux
Franck
F
Scripps Research Institute Molecular Screening Center, Lead Identification Division, Translational Research Institute, Jupiter, FL 33458, USA.
Simanski
Scott
S
Chase
Peter
P
Mishra
Jitendra K
JK
Roush
William R
WR
Ayad
Nagi G
NG
Hodder
Peter
P
D002138:Calibration; D018929:Cell Culture Techniques / Q000379:methods / Q000592:standards; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002478:Cells, Cultured; D017930:Genes, Reporter / Q000187:drug effects; D006367:HeLa Cells; D057166:High-Throughput Screening Assays / Q000379:methods* / Q000592:standards; D006801:Humans; D008156:Luciferases / Q000378:metabolism; D008904:Miniaturization / Q000379:methods; D008954:Models, Biological; D009687:Nuclear Proteins / Q000378:metabolism*; D010447:Peptide Hydrolases / Q000378:metabolism; D011480:Protease Inhibitors / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000187:drug effects / Q000378:metabolism; D014162:Transfection
D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D011480:Protease Inhibitors; D011993:Recombinant Fusion Proteins; D008156:Luciferases; D011505:Protein-Tyrosine Kinases; C499349:WEE1 protein, human; D010447:Peptide Hydrolases